Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)

NCT ID: NCT05376891Sponsor: EMD Serono Research & Development Institute, Inc.Last updated: 2026-05-08

Summary

The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.

Detailed description

This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.

Arms & interventions

Outcome measures

Primary

  • Best Overall Response (BOR)

    Time frame: Through study completion, up to approximately 4.9 years

  • Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1

    Time frame: Up to approximately 4.9 years

  • Overall Survival (OS)

    Time frame: Through study completion, up to approximately 4.9 years

  • Number of Participants with Adverse Events (AEs)

    Time frame: Up to approximately 4.9 years

  • Number of Participants with Adverse Reactions (ARs)

    Time frame: Up to approximately 4.9 years

Eligibility criteria

Sex: AllAge: All agesHealthy volunteers: No
Inclusion Criteria: * Participants who signed ICF * Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay) * Participants who are starting or are already being treated with systemic therapy Exclusion Criteria: * Participants who are enrolled in a clinical trial

Study locations (3)

Holy Cross Health

Fort Lauderdale, Florida, 33308-4603

Recruiting
David Drew · Principal Investigator

The Ohio State University Wexner Medical Center

Columbus, Ohio, 43221

Recruiting
David Carbone · Principal Investigator

Vanderbilt University Medical Center

Nashville, Tennessee, 37212

Active Not Recruiting

References

  • Thomas M, Christopoulos P, Iams WT, Mazieres J, Cortot AB, Peled N, Minuti G, Smit EF, Audhuy F, Berghoff K, Eggleton SP, Fries F, Hildenbrand M, Liu P, Mahmoudpour SH, Menzel C, Oksen D. MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy. J Comp Eff Res. 2025 Feb;14(2):e240127. doi: 10.57264/cer-2024-0127. Epub 2025 Jan 21.(PubMed)
Met Non Small Cell Cancer Registry (MOMENT) | Cancerify